Kezar Life Sciences Shares Rise After Interim Results from the MISSION Phase 2 Trial for Patients with Lupus Nephritis
Kezar Life Sciences, Inc. (NASDAQ: KZR) jumped more than 35% on Tuesday after the biotechnology company announced interim results from the Phase 2 portion of its MISSION clinical trial evaluating KZR-616, a first-in-class selective immunoproteasome inhibitor, in patients with active,...